Ventilator News and Research RSS Feed - Ventilator News and Research

New breakthrough drug shows promise to fight antibiotic-resistant infections

New breakthrough drug shows promise to fight antibiotic-resistant infections

A New York pharmaceutical company, TGV-Laboratories, has developed a groundbreaking drug that shows promise in treating a wide variety of antibiotic-resistant fungal and bacterial infections. [More]
Bridion injection approved to reverse effects of neuromuscular blocking drugs used during certain types of surgery

Bridion injection approved to reverse effects of neuromuscular blocking drugs used during certain types of surgery

The U.S. Food and Drug Administration today approved Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, which are used during certain types of surgery in adults. [More]
Queen's University Belfast-led study examines potential of new technology that could save lives in ICUs

Queen's University Belfast-led study examines potential of new technology that could save lives in ICUs

A potentially revolutionary new technology - that could saves thousands of lives in Intensive Care Units around the world - is being trialled in a UK study co-led by Queen's University Belfast. [More]
Study: Post hospital syndrome is significant risk factor for patients undergoing elective surgery

Study: Post hospital syndrome is significant risk factor for patients undergoing elective surgery

A condition known as "post hospital syndrome" (PHS) is a significant risk factor for patients who undergo elective outpatient surgery, a Loyola study has found. [More]
CareFusion to display new respiratory solutions at AARC Congress

CareFusion to display new respiratory solutions at AARC Congress

CareFusion, a BD company, will be displaying new respiratory solutions that are designed to put patients first, whether ventilated or breathing on their own, at the American Association for Respiratory Care Congress being held Nov. 7-10 in Tampa, Fla. [More]
Mallinckrodt announces approval of INOmax for cardiovascular surgery in Australia and Japan

Mallinckrodt announces approval of INOmax for cardiovascular surgery in Australia and Japan

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that INOmax (nitric oxide) for inhalation has received regulatory approval in Australia and Japan for pulmonary hypertension in conjunction with heart surgery. [More]
Strensiq approved for treatment of patients with juvenile-onset HPP

Strensiq approved for treatment of patients with juvenile-onset HPP

Today, the U.S. Food and Drug Administration approved Strensiq (asfotase alfa) as the first approved treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP). [More]
Simple tool can predict individual's life support needs five years in advance

Simple tool can predict individual's life support needs five years in advance

It is now possible to determine which patients have an increased chance of one day needing life support with mechanical ventilation. Researchers have developed a simple tool to predict an individual's five-year risk of requiring this care. [More]
Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Allergan plc today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San Diego. [More]
New study calls for new treatments for carbapenem-resistant Enterobacteriaceae infection

New study calls for new treatments for carbapenem-resistant Enterobacteriaceae infection

Researchers at The Medicines Company presented data from a multi-national cohort that demonstrates the mortality and morbidity, and poor outcomes, associated with current therapies in patients with infections due to carbapenem-resistant Enterobacteriaceae (CRE). The data from this analysis has guided the design of the company’s on-going clinical studies of its Phase 3 compound, CARBAVANCE® (meropenem/RPX7009) and was presented at the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy and Infection (ICC) joint meeting in San Diego, CA. [More]
Higher doses of hydrocortisone not linked to neurodevelopmental impairments in low birth weight infants

Higher doses of hydrocortisone not linked to neurodevelopmental impairments in low birth weight infants

Hydrocortisone is one of the 15 most frequently prescribed medications in extremely low birth weight (?1000 g) infants in the newborn intensive care unit (NICU). [More]
Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to AR-301, the Company's fully human anti-Staphylococcal alpha-toxin IgG1 monoclonal antibody (mAb). [More]
Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics Inc., a subsidiary of Vernalis plc, today announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to adult patients and physicians in the United States. [More]
Organ donor honored at Reagan UCLA Medical Center

Organ donor honored at Reagan UCLA Medical Center

Two years ago, Rachel Greenberg went out to run a few errands. While she was gone, her husband Glenn suffered a massive brain hemorrhage. He was immediately taken to Ronald Reagan UCLA Medical Center where physicians explained he had suffered the worst kind of brain bleed. [More]
Innovation in anaesthesia: an interview with Matti Lehtonen, GE Healthcare

Innovation in anaesthesia: an interview with Matti Lehtonen, GE Healthcare

The spectrum of patients seen today, from pre-term infants to the morbidly obese to the longer living elderly, is wider than ever before and increasingly more challenging with patients often presenting with multiple co-morbidities. This puts a huge strain on healthcare providers who are facing increasing challenges such as cost pressure and staff shortages. [More]
Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains. [More]
Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to its fully human monoclonal antibody Aerucin for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa. [More]
Basilea announces UK launch of broad-spectrum Cephalosporin Zevtera for first-line treatment of pneumonia

Basilea announces UK launch of broad-spectrum Cephalosporin Zevtera for first-line treatment of pneumonia

Basilea Pharmaceutica AG today announces the UK launch of its broad-spectrum Cephalosporin Zevtera (Ceftobiprole medocaril) for the first-line treatment of serious bacterial pneumonia. [More]

Warm Springs Specialty Hospital of New Braunfels achieves Gold Seal of Approval for Respiratory Failure Certification

Warm Springs Specialty Hospital of New Braunfels, a Post Acute Medical facility, today announced that it has earned The Joint Commission's Gold Seal of Approval for Respiratory Failure Certification. The Gold Seal of Approval is a symbol of quality that reflects an organization's commitment to providing safe and effective patient care. [More]

Critical care Breathe Technologies Life2000 Ventilation System receives FDA clearance

Breathe Technologies, Inc., a developer and manufacturer of medical technologies for patients with respiratory insufficiency and neuromuscular diseases, announced today that the U.S. Food and Drug Administration has granted 510(k) clearance for its critical care Breathe Technologies Life2000 Ventilation System, which is intended to provide continuous or intermittent ventilatory support for the care of individuals who require mechanical ventilation. [More]
Advertisement
Advertisement